Lantern Pharma (LTRN) Announces Extension of Existing Share Repurchase Program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Lantern Pharma Announces Extension of Existing Share Repurchase Program
March 22, 2022 7:00 AM EDTDALLAS, March 22, 2022 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that its Board of Directors has authorized an extension through July 31, 2022 of Lantern's existing share repurchase program to acquire up to $7 million of the Company's common stock.
... More
